Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04345653 · ClinicalTrials.gov registry record · Phase 2

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

A Phase 2 study, sponsored by Hackensack Meridian Health.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target

NCT04345653: Completed Phase 2 study, sponsored by Hackensack Meridian Health.

NCT04345653 is a Phase 2 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04345653, a Phase 2 study, has completed, sponsored by Hackensack Meridian Health.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target

Study Summary

The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVID-19) in high-risk, healthy acute care provider participants exposed, directly or indirectly, to COVID-19 patients. There is a more than 50 years track record of safety of HCQ for treatment and prevention of various disease states. Early data on use of HCQ for COVID treatment suggests anti-viral activity and immunomodulatory properties for reducing inflammation associated with COVID-19.

Primary Outcome

To evaluate the feasibility of this protocol including participants' recruitment within the estimated time frame, i.e. understand the ability of the team to identify eligible participants, enroll them, retain them and follow them up until study completion.

Interventions

  • DRUG Hydroxychloroquine Sulfate (HCQ)

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2020-04-14
Est. Completion 2021-05-10
Phase Phase 2
Hackensack Meridian Health

90 total trials

What the finished NCT04345653 record still lists

NCT04345653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).

The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine Sulfate (HCQ) is the first listed.

NCT04345653 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04345653 about?

NCT04345653 is a clinical study titled "Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers". The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVI...

What is the current status of trial NCT04345653?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-04-14. Estimated completion is 2021-05-10.

What interventions are being tested in trial NCT04345653?

The interventions under investigation include: Hydroxychloroquine Sulfate (HCQ) (DRUG).

Who is sponsoring clinical trial NCT04345653?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04345653's enrollment target sits among peer trials

48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04345653, the US trial registry maintained by the National Library of Medicine. NCT04345653 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.